Drug Trial Radar · NCT07450053
A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Mar 6, 2026
Primary completion
Jul 18, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation study to evaluate the safety, tolerability, PK/PD profile, and immunogenicity of a single subcutaneous dose of GenSci134 in children with idiopathic short stature (ISS). Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with ISS. It will also evaluate PK/PD profile, immunogenicity, and biomarkers to support dose selection for Phase III.
Conditions
- Idiopathic Short Stature
Interventions
GenSci134 InjectionDrug
only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.
Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)Drug
multiple doses of Norditropin® FlexPro® quaque die (QD) for 28 consecutive days by subcutaneous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 to Day 35
- Phase II: Annualized height velocity (AHV) at Week 24 of treatmentTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.